Clinical Trial Protocol
Iranian Registry of Clinical Trials

10 Jun 2026

Effect of Spironolacton on Choroidal Vascular Index in Patients with Central Serous Chorioretinopathy

Protocol summary

Summary

The aim of this study was to evaluate the effect of spironolactone on the choroidal vascular index in patients with central serous chorioretinopathy. All patients with central serous chorioronopathy who have recently been diagnosed and have not received treatment have been included in the study. Patients who have received any treatment related to central serous chorioronopathy, including intravitreal injection of bevasizumab (Avastin), laser therapy, photodynamic therapy and drug therapy, everybody who has been missed the follow-up of the treatment or are having side effects due to drug use, are excluded from the study. The population of the study was referring to al-zahra eye hospital in Zahedan, which is randomly assigned to two groups of 15 patients. A group of oral drug spironolactone and another group received placebo. Duration of treatment is six months and the patients be evaluated 1 month, 3 months and six months after initiation of therapy and finally the effect of spironolactone on the choroidal vascular index and central retinal thickness will be studied. We expect that the visual acuity of the patients will also increase as the central retinal thickness decreases.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2017101536801N1**
Registration date: **2017-11-19, 1396/08/28**
Registration timing: **prospective**

Last update:
Update count: **0**

Registration date

2017-11-19, 1396/08/28

Registrant information

Name
Alireza Ataollahi
Name of organization / entity
Zahedan University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 54 3322 4991
Email address
ataollahi.med@gmail.com

Recruitment status

Recruitment complete

Funding source

Zahedan University of Medical Sciences

Expected recruitment start date

2017-12-22, 1396/10/01

Expected recruitment end date

2018-12-22, 1397/10/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Effect of Spironolacton on Choroidal Vascular Index in Patients with Central Serous Chorioretinopathy

Public title

Effect of Spironolactone on Treatment of Central Serous Chorioretinopathy

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: All patients with central serous chorioretinopathy, whose condition has just been diagnosed and who have not received any treatment.
Exclusion criteria: Patients whohave been received any

treatment for central serous chorioretinopathy, including intravitreal injection of bevasizumab, laser therapy, photodynamic therapy, and drug treatment; Failure to refer patients for follow-up treatment; Drug-related complications requiring drug discontinuation; Disagreement with the proposed treatment

Age
No age limit

Gender
Both

Phase
N/A

Groups that have been masked
No information

Sample size
Target sample size: **30**

Randomization (investigator's opinion)
Randomized

Randomization description

Blinding (investigator's opinion)
Single blinded

Blinding description

Placebo
Used

Assignment
Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee
Zahedan university of Medical Sciences

Street address
Faculty of medicine، Jannat Boulvar, Dr. Hesabi sq.

City
Zahedan

Postal code
98167-43175

Approval date
2017-09-10, 1396/06/19

Ethics committee reference number
IR.ZAUMS.REC.1396.123

Health conditions studied

1

Description of health condition studied
Central Serous Chorioretinopathy

ICD-10 code
H35.7

ICD-10 code description
Separation of Retinal Layers

2

Description of health condition studied
Central Serous Chorioretinopathy

ICD-10 code
H33.2

ICD-10 code description
Serous retinal detachment

Primary outcomes

1

Description
Macular Central Thickness

Timepoint
At the beginning - One month later - Three months later - Six months later

Method of measurement
Based on OCT, Measured as the Thickness of the Macular Center

2

Description
Choroidal Vasculai Index

Timepoint
At the beginning - One month later - Three months later - Six months later

Method of measurement
The ratio of the luminal area to the total choroid tissue in the subfovea area using the image J software

3

Description
Visual Acuity

Timepoint
At the beginning - One month later - Three months later - Six months later

Method of measurement
Snellen Chart

4

Description
Recovery

Timepoint
Six months later

Method of measurement
Increase in visual acuity or a decrease in the thickness of the macula to less than 252 micrometers, or a rise in the choroid vascular index

Secondary outcomes

1

Description
Recurrence

Timepoint
At 1 year

Method of measurement

Based on OCT measurements, which, with the increase in the thickness of the macular center, precipitates as fluid re-accumulation in the sub-retinal substrate after the fluid has completely disappeared.

Intervention groups

1

Description
Tablet Spironolactone 100 mg Once Daily Orally for 6 Months and macular OCT will be obtained 1 month, 3 months and 6 months after initiation of therapy.
Category
Treatment - Drugs

2

Description
Placebo (Eye drop Artificial tears) q6hr Topical for 6 Months and macular OCT will be obtained 1 month, 3 months and 6 months after initiation of therapy.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Zahedan University of Medical Sciences
Full name of responsible person
Alireza Ataollahi
Street address
Faculty of medicine، Jannat Boulvar, Dr. Hesabi sq.
City
Zahedan

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Zahedan University of Medical Sciences
Full name of responsible person
Noormohammad Bakhshani
Street address
Faculty of medicine، Jannat Boulvar, Dr. Hesabi sq.
City
Zahedan
Grant name
طرح هزینه بر نمی باشد.
Grant code / Reference number
ندارد.
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Zahedan University of Medical Sciences
Proportion provided by this source
100
Public or private sector
empty
Domestic or foreign origin
empty
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
empty

Person responsible for general inquiries

Contact
Name of organization / entity
Zahedan Universty of Medical Sciences
Full name of responsible person
Alireza Ataollahi
Position
Resident of Opthalmology
Other areas of specialty/work
Street address
Faculty of medicine، Jannat Boulvar, Dr. Hesabi sq.
City
Zahedan
Postal code
Phone
+98 54 3322 4991
Fax
Email
ataollahi.med@gmail.com
Web page address

Person responsible for scientific inquiries

Contact
Name of organization / entity
Al-Zahra Eye Hospital
Full name of responsible person
Alireza Maleki
Position
Fellowship of Vitreoretinal Disease
Other areas of specialty/work
Street address
Shahid Motahari Blvd (airport), Not reaching Khatam Square
City
Zahedan
Postal code
Phone
+98 54 3322 4991
Fax
Email
ataollahi.med@gmail.com eye@zaums.ac.ir
Web page address

Person responsible for updating data

Contact
Name of organization / entity
Al-Zahra Eye Hospital

Full name of responsible person
Alireza Maleki
Position
Fellowship of Vitreoretinal Disease
Other areas of specialty/work
Street address
Shahid Motahari Blvd (airport), Not reaching Khatam sq.
City
Zahedan
Postal code
Phone
+98 54 3322 4991
Fax
Email
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
empty
Study Protocol
empty
Statistical Analysis Plan
empty
Informed Consent Form
empty
Clinical Study Report
empty
Analytic Code
empty
Data Dictionary
empty